Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Clinical Oncology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,679 result(s) found for: Clinical Oncology. Displaying page 1 of 134.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-004753-87 Sponsor Protocol Number: BBI608-901 Start Date*: 2020-03-18
    Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc.
    Full Title: A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Sumitomo Dainippon Pharma Oncology, Inc. sponsored Napabucasin Protocols
    Medical condition: Metastatic Pancreatic Adenocarcinoma and Metastatic Colorectal Cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000974-44 Sponsor Protocol Number: D910CC00001 Start Date*: 2019-10-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer ...
    Medical condition: Metastatic Microsatellite-Stable Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002540-25 Sponsor Protocol Number: CSTI571A2406 Start Date*: 2013-02-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multi-center imatinib roll-over protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued ima...
    Medical condition: Male and female patients who are currently enrolled in a Novartis-sponsored, Oncology OGD&GMA imatinib study, are benefiting from treatment with imatinib and have fulfilled all their requirements ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003844-11 Sponsor Protocol Number: ML29242 Start Date*: 2015-04-27
    Sponsor Name:Department of Oncology, Linköping University Hospital, Linköping, Sweden
    Full Title: Continous treatment with bevacizumab in elderly patients with mCRC: an open label, single arm, prospective phase IV trial to evaluate outcome and safety of continuous bevacizumab treatment in combi...
    Medical condition: Metastatic colorectal cancer
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004981-14 Sponsor Protocol Number: OOI/KEMB/2006-2 Start Date*: 2006-12-20
    Sponsor Name:National Institute of Oncology, Budapest, Hungary
    Full Title: Phase II., non randomized, open study: inoperable gall bladder or biliary tract EGFR expressing carcinoma treatment with Erbitux and 5-fluorouracil, epiadriamycin, mitomycin containing combination ...
    Medical condition: Irresectable biliary tract cancer where palliation is the aim. It could be locally extanded and also metastatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006755-12 Sponsor Protocol Number: COU-AA-001Ext Start Date*: 2007-03-06
    Sponsor Name:Janssen Oncology, Inc.
    Full Title: An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001
    Medical condition: Hormone refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003564-72 Sponsor Protocol Number: Start Date*: 2012-01-13
    Sponsor Name:Aarhus University Hospital [...]
    1. Aarhus University Hospital
    2. Aarhus University Hospital
    Full Title: A Randomised phase II study with the combination of Xeloda (Capecitabine) plus Navelbine Oral ( Vinorelbine) day 1 and day 8 every 3. week versus Xeloda plus Navelbine Oral given metronimic as 1. o...
    Medical condition: Patient with relapse of breast cancer will be randomised for two different chemotherapy regimes ( 2 treatments arms)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-002210-22 Sponsor Protocol Number: COU-AA-003-EXT Start Date*: 2008-09-25
    Sponsor Name:Janssen Oncology, Inc.
    Full Title: An Extended Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy and Completed Clinical Study COU-AA...
    Medical condition: Hormone refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001533-28 Sponsor Protocol Number: AAML0531 Start Date*: 2016-05-03
    Sponsor Name:Children's Oncology Group
    Full Title: A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
    Medical condition: Acute myeloid leukaemia
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001049-42 Sponsor Protocol Number: Start Date*: 2012-07-05
    Sponsor Name:Department of Oncology, Rigshospitalet
    Full Title: MRI-perfusion and FLT- and FET-PET during bevacizumab monotherapy for patients with recurrent Glioblastoma Multiforme
    Medical condition: Recurrent Glioblastoma multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001545-41 Sponsor Protocol Number: KO-MEN-001 Start Date*: 2021-09-09
    Sponsor Name:Kura Oncology, Inc.
    Full Title: A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Medical condition: Relapsed and/or refractory Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004281-10 Sponsor Protocol Number: PT/11/2017 Start Date*: 2018-01-10
    Sponsor Name:Department of Pediatric oncology, Aarhus University hospital
    Full Title: Pharmacokinetics and pharmacodynamics of Piperacillin-Tazobactam (PT) in pediatric oncology patients with fever and neutropenia
    Medical condition: Pediatric oncology patients with fever
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10051312 Neutropenic fever LLT
    20.0 100000004851 10076734 Chemotherapy induced neutropenia LLT
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-000494-20 Sponsor Protocol Number: ABC-SE Start Date*: 2016-07-03
    Sponsor Name:Skåne University Hospital, Department of Oncology
    Full Title: A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Based Treatment with Focus on Mechanisms of Resistance to Endocrine Based Treatment (fulvestrant/aroma...
    Medical condition: Estrogen receptor positive metastatic or locally advanced inoperable breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002968-10 Sponsor Protocol Number: 024 Start Date*: 2008-01-17
    Sponsor Name:Department of Medicine I, Clinical Dep. f. Oncology, University Hospital,
    Full Title: Treatment of Patients Suffering from Tumour Cachexia with Dronabinol (tetrahydrocannabinol) or Placebo Comparison of individually optimised dosages in a double blind, randomised parallel design
    Medical condition: tumour cachexia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001396-69 Sponsor Protocol Number: KO-TIP-002 Start Date*: 2016-10-27
    Sponsor Name:Kura Oncology Inc.,
    Full Title: An Open Label Phase II Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell LymphomaLymphoma
    Medical condition: Subjects with Relapses and Refractory Peripheral T-Cell Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-001811-16 Sponsor Protocol Number: PS21GAP Start Date*: 2022-12-19
    Sponsor Name:Princess Maxima Center for pediatric oncology
    Full Title: 68Ga-SATO in pediatric neuroblastoma patient; exploratory, safety, non-randomized, open label, comparative study
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004362-26 Sponsor Protocol Number: I3Y-MC-JPCF Start Date*: 2017-08-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High-Risk, Node-Positive, ...
    Medical condition: Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) HU (Ongoing) GB (GB - no longer in EU/EEA) BE (Ongoing) DK (Trial now transitioned) FI (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) CZ (Ongoing) FR (Ongoing) PT (Trial now transitioned) IT (Ongoing) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-004796-40 Sponsor Protocol Number: 2018_58 Start Date*: 2020-06-11
    Sponsor Name:CHU de Lille
    Full Title: Multicenter Phase II study with dose-light escalation, intraoperative glioblastoma photodynamic therapy
    Medical condition: Glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000878-11 Sponsor Protocol Number: OMO1.01.02 Start Date*: 2017-06-08
    Sponsor Name:OCTIMET Oncology NV
    Full Title: A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanc...
    Medical condition: Locally advanced, unresectable or metastatic solid malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005070-11 Sponsor Protocol Number: M13-694 Start Date*: 2015-07-08
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or I...
    Medical condition: Newly diagnosed, untreated Stage III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed) ES (Restarted) PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:47:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA